Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
Tags :Vischer
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
Vischer announced the addition of Karin Graf (pictured) to the firm’s litigation and arbitration team, in the role of partner. Graf assumes her new role as of September 1st. Graf brings with her more
Vischer’s dispute resolution team successfully represented a Swiss bank in a multi-faceted conflict, defending against allegations of corruption and breaches of contract as well as massive claims for damages. The dispute included commercial court
Biopharmaceutical company Relief Theraputics Holding, has a binding agreement with two institutional U.S. investors completed. The contract provides for the purchase of Relief shares with a total value of CHF 15 million, which come from
Atlas Antibodies, a global developer of advanced reagents for biomedical research based in Sweden, has agreed to acquire Evitria Group from its shareholders. The transaction closed on August 5, 2021. Vischer advised the sellers on this
Rigeto portfolio company Swissphone acquires instaSolution, a provider of modern and efficient communication and management solutions in the areas of alerting, crisis management, mobile collaboration, messaging and IoT. The transaction closed on July 16, 2021. Vischer
Relief Therapeutics Holding, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, has issued 1,000,000,000 additional registered shares out of the authorised share capital approved by the Annual
H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per
